Medicinski Glasnik (Feb 2011)
Cystatin C in sera of patients with aggressive non-Hodgkin B-cell lymphoma
Abstract
Aim To investigate the cystatin C levels in sera of patients with aggressive non-Hodgkin B-cell lymphoma. Methods The levels of cystatin C in sera of lymphoma patients and control group consisted of healthy individuals, were measured by using speciic sandwich-type ELISA. For each patient the clinical stage of disease was determined according to Ann Arbor staging system for lymphomas. Results Our study shows that mean cystatin C serum level in the patients group (1056 ± 65 ng/mL) was signiicantly higher when compared with the mean level of the healthy control group (819 ± 28 ng/mL) (P=0,001). Mean cystatin C level of the group with clinical stages III and IV (1255 ± 109 ng/mL) was signiicantly elevated when compared with the mean level of the group with clinical stages I and II (896 ± 51 ng/mL) (P=0,03). Conclusion This inding points out a connection between inhibitor level and aggressive behaviour of lymphoma and could be considered for further strategies of prognosis of the disease.
